Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. - Test2 - elhamkhani - TriplyDB

Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.

Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.

http://www.wikidata.org/entity/Q34150923

about

Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Emergent Complications in the Pediatric Hematopoietic Stem Cell Transplant Patient Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients.In vitro study of the variable effects of proton pump inhibitors on voriconazole Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children.Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults.Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients.Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis.Current concepts in antifungal pharmacology.Invasive aspergillosis in children with acquired immunodeficiencies.The use of antifungal therapy in neonatal intensive care.Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice.Antifungal therapy in children: an update.Antifungal agents in current pediatric practice.Invasive candidiasis and candidaemia in neonates and children: update on current guidelines.Clinical pharmacology of antifungal agents to overcome drug resistance in pediatric patients.Invasive Fusariosis: A Single Pediatric Center 15-Year Experience.Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.Pharmacokinetic considerations in treating invasive pediatric fungal infections.Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.Use of Fungal Diagnostics and Therapy in Pediatric Cancer Patients in Resource-Limited Settings.Successful treatment of Aspergillus ventriculitis through voriconazole adaptive pharmacotherapy, immunomodulation, and therapeutic monitoring of cerebrospinal fluid (1→3)-β-D-glucan.Efficacy of voriconazole in a murine model of acute Trypanosoma cruzi infection.Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre.Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.The Clinical Significance of Voriconazole Therapeutic Drug Monitoring in Children With Invasive Fungal Infections.Autoinduction of voriconazole metabolism in a child with invasive pulmonary aspergillosis.Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients.Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis.Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children.

P2860

Q27009221-3FD24119-2B39-4431-9A99-6E02FA7EF4C3 Q27025299-DE0B9522-6CED-45C2-B5FB-8076336DA410 Q34138276-E66C5320-2EC0-489A-B850-D1AED7844CC2 Q34212799-4F1AFCAC-BB31-4A01-B2C3-CE687C028CD3 Q34522746-6FDB9152-3B11-48B4-BB92-F99214062D0F Q34532546-CADA7BFC-3378-4C3F-8401-AD79ACFE3A4C Q35105949-2BE0BA6B-4991-4EFC-B945-975A5A5BA6A9 Q35598464-96CA2F0F-C3A4-4819-8B2F-A45F57025282 Q35598532-65A8A275-D0CC-4EF2-B06B-481DAE6FBE4F Q35715408-E161C9C9-51ED-477B-8AC9-4F1FB7988059 Q35960842-D9C9218F-DC69-4118-9120-0D63DF896F7D Q35973357-36C086C9-DE72-4FAD-BC80-9102ABBB29DD Q35973543-E8BC3292-2D39-47EF-ACAB-09C64E88CDBC Q36018595-408222F2-1C2B-4A0C-A39D-4C3C3BFBE288 Q36505462-4FD9FD35-2303-468C-A70E-9E0139418A55 Q36608562-858990B7-5AAF-4508-8AAE-7EB19A80F216 Q37693296-38E25B7A-6D1C-4601-A407-218129B40137 Q37908856-1F1AA2EE-B644-4B45-B8B0-DB7190D0B354 Q37954958-44E929BA-66CD-4144-A2F1-F91020B3FDD5 Q37985070-DDE9A18A-3EE5-4B67-822D-AE25C5E70D6C Q37993110-F1583CE3-FAEA-44F4-B23A-42A6281C98DB Q38015090-CA9FFED3-C873-4D80-A431-B58B4CE50EA3 Q38101520-3F88F189-123D-4847-BBA4-DF7AEC33E259 Q38263282-6C2F47FB-0A28-4CD4-9CCC-87883BFCB5F8 Q38314467-B06C2DAC-3BBB-4068-926B-58203352EF09 Q38592939-26D55783-62DA-405E-A967-779704645994 Q38775809-239AA49F-7D59-4883-B89E-3814D342A56E Q38816614-02DA323A-C4DE-4273-9319-567462C3B9CD Q38880522-51A2D39F-3D7F-4259-8F3E-A7479E3EBC56 Q38965488-45C9D523-2BAD-4A0C-AAA1-5D9C34FD83A0 Q39006744-782592CE-AE3F-4E0F-81BE-E11B21F9A75C Q39508383-059E1417-DDD0-493A-B3EF-5C589058626B Q39893350-03139AA4-0F4C-4292-BD73-6F4B9B09E23F Q40290020-2B53F8B5-558E-4F6D-A0B3-22CA68414464 Q40407579-B9313D3A-A467-45A4-B325-34A887408AC6 Q40913870-3335ADAA-73CC-4D38-9A03-DC425951C1A8 Q41057395-6C38FB3C-339A-436A-8EFC-F3F565003B07 Q44294733-DC17BBA4-472D-4E41-90D4-8D77D5CADC9A Q45158220-9C536E0A-EB6E-40C5-9483-2226D4A27DB7 Q47781187-B1906E80-E194-4E93-A6EF-5A40C1A1B91F

P2860

Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.

http://www.wikidata.org/entity/Q34150923

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.

@ast

Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.

@en

Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.

@nl

type

label

Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.

@ast

Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.

@en

Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.

@nl

prefLabel

Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.

@ast

Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.

@en

Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.

@nl

P1433

Q34150923-DA1251FA-8CD0-4079-BAA1-BFE27DAFA585

P1476

Q34150923-86C7C6DF-56FF-4022-9A7F-FB0FBCC012BD

P2093

Q34150923-29091029-6A58-407E-AE29-C897815DAEF9

Q34150923-5D7C4FAC-5100-4D4D-83E8-4260F4D1E401

Q34150923-A5184498-026A-40FF-9860-28A4304BA22D

Q34150923-ABEBA3B2-2482-41EE-B1A9-71047438CE3A

Q34150923-B7248D87-8F91-442A-B0D4-8CE5B15E4F0D

Q34150923-E252C235-AA79-4704-9FB7-40AF0E22D1F1

Q34150923-EC8371DC-37A8-46F4-A0BC-C9669F6D2864

Q34150923-F3021FBD-F99E-4510-B9BF-59114D0EC09F

P2860

Q34150923-025AF4DE-A5B2-405F-81D7-FD5C15E359E6

Q34150923-080B63B0-348F-4705-ABC9-03307F154735

Q34150923-11322D9C-B625-4D7A-990F-1CF52C8A6BC2

Q34150923-3708BED1-260E-43DB-9E40-481282B3BAEB

Q34150923-55514750-6CC6-4879-BB78-1032B0187DB3

Q34150923-633100A5-10AE-435F-9F27-CE58B403135B

Q34150923-6E2495B6-84EB-4A9B-B9C1-F28F635B4B2A

Q34150923-7A88CCF0-E842-4C65-9F3D-683C5982C92F

Q34150923-8468852D-E75C-4CB4-8872-953C4959D993

Q34150923-91514109-44B3-4A8E-B5F2-54852404B52C

P304

Q34150923-AB959017-81DB-45A0-8978-8932064D9CCA

P31

Q34150923-3737A06A-10E2-472F-938F-40120CF7B9B8

P356

Q34150923-0FDE99E0-6257-445C-86B6-7789F3E52051

P407

Q34150923-628408E2-CC8A-4164-8806-D69AC8906E32

P433

Q34150923-8DDBC256-D862-4B13-833E-B6D9FAD45452

P478

Q34150923-8A100CE4-C14A-4191-ABCE-814301C2FD35

P50

Q34150923-B703A241-875D-4D86-AA90-033D88B47870

Q34150923-C4E973DC-EFAA-4D36-9D68-89AEDB1A66CA

P577

Q34150923-1066EA08-4597-4441-A3BA-44D2ED3CB8DE

P698

Q34150923-9A7EBF4D-DE9A-4749-9B25-C722B2A39C7B

P932

Q34150923-13356555-D57D-45DE-9FAE-A8301103A51E

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.

@en

P2093

Andreas H Groll

http://www.w3.org/2001/XMLSchema#string

Antonio C Arrieta

http://www.w3.org/2001/XMLSchema#string

Haran Schlamm

http://www.w3.org/2001/XMLSchema#string

Nigel J Klein

http://www.w3.org/2001/XMLSchema#string

Nolan D Wood

http://www.w3.org/2001/XMLSchema#string

Peter A Milligan

http://www.w3.org/2001/XMLSchema#string

Thomas J Walsh

http://www.w3.org/2001/XMLSchema#string

Timothy Driscoll

http://www.w3.org/2001/XMLSchema#string

P2860

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

Biochemistry and molecular biology of the human CYP2C subfamily

Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.

Voriconazole pharmacokinetics and pharmacodynamics in children.

Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.

Voriconazole -- better chances for patients with invasive mycoses.

Voriconazole therapy in children with cystic fibrosis.

Mycoses in pediatric patients.

P304

4116-4123

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00896-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20660687

http://www.w3.org/2001/XMLSchema#string

P932

2944563

http://www.w3.org/2001/XMLSchema#string